We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Icagen Announces Appointment of Chairman

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Icagen Announces Appointment of Chairman "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Icagen, Inc. has announced that Charles A. Sanders, M.D., who has served on the Icagen Board of Directors since 1997, has been appointed Chairman of Icagen's Board of Directors.

Dr. Sanders' appointment follows the resignation from Icagen's Board of Directors of H. Jefferson Leighton, Ph.D., who has served as Chairman since 1992.

Dr. Sanders has over forty years of experience in the pharmaceutical industry and academic medicine.

Dr. Sanders served as chairman and chief executive officer of Glaxo Inc. from 1989 to May 1995, and also served as a member of the board of directors of Glaxo plc.

Previously, Dr. Sanders was general director of Massachusetts General Hospital and professor of medicine at Harvard Medical School.

Dr. Sanders is a director of several publicly traded companies, including TrimerisGenentech and Fisher Scientific International.

He is currently a member of the Institute of Medicine of the National Academy of Sciences, a member of the CSIS Board of Trustees, chairman of Project HOPE and chairman of the Foundation for the National Institutes of Health.

Dr. Sanders is also past chairman of the New York Academy of Sciences, past chairman of The Commonwealth Fund and past chairman of the Harvard Overseers Committee to Visit the Harvard Medical School.

Dr. Sanders received his M.D. from Southwestern Medical College of the University of Texas.

Jeff Leighton, Ph.D. stated, "After more than twelve years of service on the Icagen Board, I have decided to retire from this position entirely for family reasons."

"It has been a privilege to work with the management team and the Board of Directors at Icagen during this period."

"I continue to believe strongly in the approach of targeting ion channels for the development of novel pharmaceuticals and believe that Icagen is extremely well positioned to continue its research and development efforts in this field."

P. Kay Wagoner, Ph.D., Chief Executive Officer of Icagen, noted, "We thank Jeff for his many years of service on the Icagen Board. Since the Company's inception in 1992, his guidance and counsel have been invaluable."

"Jeff's presence on the Icagen Board will be greatly missed, and we wish him the very best in all his future endeavors. At the same time, we are delighted that Charles Sanders has been appointed our new Chairman."

"His many years of experience in the pharmaceutical industry and medical community will be of great value to the Company as we continue our mission to discover and develop novel pharmaceuticals based upon our core ion channel technology platform."

Dr. Sanders commented, "I thank the Board for this opportunity to serve as Chairman, and look forward to continuing to work with the management team and Board at Icagen as the Company continues to advance its pipeline of clinical and preclinical compounds."

"Speaking for the entire Board, I wish Jeff the very best, and thank him for his many years of dedicated service to the Company."